×

Medgenics to Present at Two Upcoming Healthcare Investor Conferences

Medgenics, Inc. logo

WAYNE, Pa. and MISGAV, Israel, June 16, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that members of the senior management team will be participating in the following upcoming healthcare investor conferences.

  • Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014 at the Yale Club in New York, NY. Dr. Garry Neil, Global Head of Research and Development, will participate in a panel entitled Novel Delivery Approaches: Evolving an Evolving Field at 2:35 p.m. ET.
  • 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at the Westin New York Grand Central in New York, NY. Dr. John Leaman, Chief Financial Officer, will present at 3:30 p.m. ET.

About Medgenics

Medgenics is developing and commercializing BioPump™, a proprietary platform for the sustained production and delivery of therapeutic proteins using ex vivo gene therapy and the patient's own tissue for the treatment of orphan and rare diseases. For more information, visit the Company's website at www.medgenics.com.

Forward-looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

CONTACT: Medgenics, Inc. John Leaman john.leaman@medgenics.com Stern Investor Relations Beth DelGiacco 1 212 362 1200 beth@sternir.com

Source:Medgenics, Inc.

More From Press Releases